Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 25
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Pharm Dev Technol ; 29(3): 248-257, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38416122

RESUMEN

This study aimed to develop a tablet that shows a drug release profile similar to the tofacitinib sustained-release tablet (Xeljanz XR®; OROS™) using hot melt extrusion technology. Tofacitinib citrate was selected as the drug. HPMCAS, HPMCP, and Kollidon VA64 were used as thermoplastic polymers to prepare a hot-melt extrudate. The extrudate was obtained from a twin screw extruder and pelletizer. The granules were compressed using a single punch press machine and then coated. TGA, DSC, XRD, FT-IR, and SEM were performed on the hot melt extrudate to understand its physicochemical properties. Dissolution tests were performed using the paddle method (USP Apparatus II). The results showed that the crystallinity state of tofacitinib changed to amorphous after the hot melt extrusion process; however, no chemical change was observed. The drug release profile was similar to that of Xeljanz XR®, which has an initial lag time owing to its OROS™ formulation; a coating process was performed to obtain a similar drug release profile. The lag time was controlled by adjusting the thickness of the coating layer. Moreover, the extrudate size and compression force during tableting did not significantly affect drug release. In conclusion, the new tofacitinib sustained-release tablet prepared using hot melt extrusion showed a drug release behavior similar to that of Xeljanz XR®.


Asunto(s)
Tecnología de Extrusión de Fusión en Caliente , Calor , Piperidinas , Pirimidinas , Tecnología de Extrusión de Fusión en Caliente/métodos , Preparaciones de Acción Retardada/química , Solubilidad , Espectroscopía Infrarroja por Transformada de Fourier , Comprimidos/química , Liberación de Fármacos , Composición de Medicamentos/métodos
2.
Drug Des Devel Ther ; 16: 4279-4289, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36561308

RESUMEN

Purpose: This study aimed to ensure the convenience of administration and reproducibility of efficacy, regardless of the meal, by improving the solubility of rivaroxaban (RIV). Methods: RIV is a non-vitamin K antagonist oral anticoagulants that exhibits a coagulation effect by directly inhibiting coagulation factor Xa. However, RIV has a very low solubility; therefore, it must be administered with a meal at high doses. We used a drug- hydroxypropyl-beta-cyclodextrin (CD)-water-soluble polymer triple complex (R-C-P complex) to solubilize RIV. Using Minitab, we evaluated the effect of each factor on RIV solubility and developed an optimal R-C-P complex formulation. The amount of CD, amount of polymer, and polymer type were set as the independent variables X1, X2, and X3, respectively. RIV solubility (Y1) and dissolution rate for 45 min in pH 4.5 medium (Y2) and pH 1.2 medium (Y3) were set as response variables. Results: The most efficient RIV solubilization effect was obtained from the composition using CD and HPMC 2208, and physicochemical properties and dissolution parameters were analyzed. RIV in the R-C-P complex was present in an amorphous form and showed high solubility. Unlike commercial products, it showed a 100% dissolution rate. The R-C-P complex formulation secured high RIV solubility and 100% release regardless of pH. Conclusion: The results imply that high-dose RIV can be administered regardless of the meal, reducing the risk of changing the drug effect due to the patient's administration mistake.


Asunto(s)
Ciclodextrinas , Rivaroxabán , Humanos , Solubilidad , Reproducibilidad de los Resultados , Ciclodextrinas/química , Preparaciones Farmacéuticas , 2-Hidroxipropil-beta-Ciclodextrina , Polímeros
3.
Pharmaceutics ; 14(9)2022 Aug 25.
Artículo en Inglés | MEDLINE | ID: mdl-36145525

RESUMEN

A gastroretentive in situ oral gel containing metformin hydrochloride (Met HCl) was prepared based on sodium alginate (Sod ALG), calcium carbonate, and hydroxyethylcellulose (HEC). The optimal composition of the formulation was explored based on the design of experiments (DoE). First, a 32 full factorial design was used for formulation E1 to determine proper composition of Sod ALG and calcium carbonate. Second, a circumscribed central composite design was employed to add HEC as a thickening agent (formulation E2). The dissolution rates at 15, 30, 60, 120, and 240 min were used as responses. Partial least squares regression analysis indicated the effect of each component in delaying the release of Met HCl in the oral gel formulation. The optimized formulation E2-08 consisting of 1.88% Sod ALG, 0.63% HEC, and 1.00% calcium carbonate and two more formulations, E2-10 and E2-12 conformed to USP monograph for extended release. Other physicochemical properties, including floating lag time and duration, viscosity, and pH, measured for each batch and FT-IR spectrometry analysis showed no unexpected interaction between Met HCl and excipients. The current study suggests the potential use of a gastroretentive in situ oral gel for Met HCl helping patient compliance. This study highlights that a systematic approach based on DoE allows the formulation optimization.

4.
Pharmaceuticals (Basel) ; 14(12)2021 Dec 02.
Artículo en Inglés | MEDLINE | ID: mdl-34959655

RESUMEN

Itraconazole (ITZ) is a class II drug according to the biopharmaceutical classification system. Its solubility is pH 3-dependent, and it is poorly water-soluble. Its pKa is 3.7, which makes it a weak base drug. The aim of this study was to prepare solid dispersion (SD) pellets to enhance the release of ITZ into the gastrointestinal environment using hot-melt extrusion (HME) technology and a pelletizer. The pellets were then filled into capsules and evaluated in vitro and in vivo. The ITZ changed from a crystalline state to an amorphous state during the HME process, as determined using DSC and PXRD. In addition, its release into the gastrointestinal tract was enhanced, as was the level of ITZ recrystallization, which was lower than the marketed drug (Sporanox®), as assessed using an in vitro method. In the in vivo study that was carried out in rats, the AUC0-48h of the commercial formulation, Sporanox®, was 1073.9 ± 314.7 ng·h·mL-1, and the bioavailability of the SD pellet (2969.7 ± 720.6 ng·h·mL-1) was three-fold higher than that of Sporanox® (*** p < 0.001). The results of the in vivo test in beagle dogs revealed that the AUC0-24h of the SD-1 pellet (which was designed to enhance drug release into gastric fluids) was 3.37 ± 3.28 µg·h·mL-1 and that of the SD-2 pellet (which was designed to enhance drug release in intestinal fluids) was 7.50 ± 4.50 µg·h·mL-1. The AUC of the SD-2 pellet was 2.2 times higher than that of the SD-1 pellet. Based on pharmacokinetic data, ITZ would exist in a supersaturated state in the area of drug absorption. These results indicated that the absorption area is critical for improving the bioavailability of ITZ. Consequently, the bioavailability of ITZ could be improved by inhibiting precipitation in the absorption area.

5.
Molecules ; 25(10)2020 May 16.
Artículo en Inglés | MEDLINE | ID: mdl-32429452

RESUMEN

This study aimed to develop a novel oral drug delivery system for gastroretentive sustained drug release by using a capsular device. A capsular device that can control drug release rates from the inner immediate release (IR) tablet while floating in the gastric fluid was fabricated and printed by a fused deposition modeling 3D printer. A commercial IR tablet of baclofen was inserted into the capsular device. The structure of the capsular device was optimized by applying a design of experiment approach to achieve sustained release of a drug while maintaining sufficient buoyancy. The 2-level factorial design was used to identify the optimal sustained release with three control factors: size, number, and height of drug-releasing holes of the capsular device. The drug delivery system was buoyant for more than 24 h and the average time to reach 80% dissolution (T80) was 1.7-6.7 h by varying the control factors. The effects of the different control factors on the response factor, T80, were predicted by using the equation of best fit. Finally, drug delivery systems with predetermined release rates were prepared with a mean prediction error ≤ 15.3%. This approach holds great promise to develop various controlled release drug delivery systems.


Asunto(s)
Baclofeno/química , Preparaciones de Acción Retardada/química , Portadores de Fármacos/química , Relajantes Musculares Centrales/química , Liberación de Fármacos , Análisis Factorial , Humanos , Cinética , Impresión Tridimensional/instrumentación , Soluciones , Comprimidos
6.
Pharm Dev Technol ; 25(5): 525-534, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31985320

RESUMEN

The aim of this study was to prepare various types of solid dispersions (SDs) by the hot-melt extrusion technique. Next, process analytical technology (PAT) such as Fourier transform-infrared (FT-IR) and Raman and near infrared (NIR) spectroscopy were applied to determine the solubilization effect. The SDs and its tablets were prepared. Differential scanning calorimetry (DSC), X-ray diffraction (XRD), and scanning electron microscopy (SEM) were performed to determine the morphological and crystalline characteristics of the SDs. Additionally, PAT analyses were performed to identify the solubilization of the celecoxib. Dissolution testing was performed using the paddle method indicated in the US Pharmacopeia Apparatus II. Based on SEM, DSC, and XRD analysis, all SDs changed successfully from the crystalline to the amorphous form. However, FT-IR, Raman, and NIR analysis used in PAT showed that SDs were divided into two groups. New peaks formed as the amount of drug loading increased to >50% in the SD and the dissolution rates were lower than those of the marketed drug. Drug loading levels of ≤50% showed no new peak and exhibited strong solubilization effects. PAT tools can be used to discriminate between extrudates with poor (<50% drug release after 120 min) and desirable (>75% drug release after 120 min) dissolution performance.


Asunto(s)
Antiinflamatorios no Esteroideos/química , Celecoxib/química , Composición de Medicamentos/métodos , Tecnología de Extrusión de Fusión en Caliente/métodos , Antiinflamatorios no Esteroideos/normas , Celecoxib/normas , Dureza , Microscopía Electrónica de Rastreo , Solubilidad , Espectroscopía Infrarroja por Transformada de Fourier , Espectroscopía Infrarroja Corta , Espectrometría Raman , Comprimidos
7.
Sci Rep ; 9(1): 8248, 2019 06 03.
Artículo en Inglés | MEDLINE | ID: mdl-31160615

RESUMEN

Periodontitis is initiated by causative bacteria in the gingival sulcus. However, as the lesion is often deep and out of circulation system and biofilm is frequently formed on the bacteria cluster, use of antibacterial agents has been limited and the invasive method such as curettage is thought as an only treatment. Here we designed non-invasive photodynamic therapy (PDT), with the ointment which leads a photosensitizer deliverable into gingival sulcus. We assessed whether 650 nm light-emitting-diode (LED) penetrates the 3-mm soft tissue and effectively activates a photosensitizer toluidine-blue-O (TBO) through the thickness to remove Porphyromonas gingivalis and Fusobacterium nucleatum species. The oral ointment formulation was optimized to efficiently deliver the photosensitizer into gingival sulcus and its efficacy of PDT was evaluated in in vitro and in vivo models. Four weeks of TBO-formulation mediated-PDT treatment significantly attenuated periodontitis-induced alveolar bone loss and inflammatory cytokines production in rats. These results confirm that a 650 nm LED indeed penetrates the gingiva and activates our TBO formulation which is sufficiently delivered to, and retained within, the gingival sulcus; thus, it effectively kills the bacteria that reside around the gingival sulcus. Collectively, TBO-mediated PDT using LED irradiation has potential as a safe adjunctive procedure for periodontitis treatment.


Asunto(s)
Fusobacterium nucleatum/efectos de los fármacos , Periodontitis/tratamiento farmacológico , Periodontitis/microbiología , Fotoquimioterapia , Porphyromonas gingivalis/efectos de los fármacos , Animales , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Biopelículas/efectos de los fármacos , Resorción Ósea/patología , Liberación de Fármacos , Inflamación/patología , Masculino , Pruebas de Sensibilidad Microbiana , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/uso terapéutico , Ratas Wistar , Cloruro de Tolonio/farmacología , Cloruro de Tolonio/uso terapéutico , Viscosidad
8.
Drug Deliv ; 25(1): 1362-1371, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29869563

RESUMEN

Docetaxel (DTX)-loaded polymeric micelles (DTBM) were formulated using the triblock copolymer, poly(ethylene glycol)-polylactide-poly(ethylene glycol) (PEG-PLA-PEG), to comprehensively study their pharmaceutical application as anticancer nanomedicine. DTBM showed a stable formulation of anticancer nanomedicine that could be reconstituted after lyophilization (DTBM-R) in the presence of PEG 2000 and D-mannitol (Man) as surfactant and protectant, respectively. DTBM-R showed a particle size less than 150 nm and greater than 90% of DTX recovery after reconstitution. The robustly formed micelles might minimize systemic toxicity due to their sustained drug release and also maximize antitumor efficacy through increased accumulation and release of DTX from the micelles. From the pharmaceutical development point of view, DTBM-R showing successful reconstitution could be considered as a potent nanomedicine for tumor treatment.


Asunto(s)
Antineoplásicos/administración & dosificación , Antineoplásicos/química , Poliésteres/química , Polietilenglicoles/química , Polímeros/química , Taxoides/química , Animales , Línea Celular Tumoral , Química Farmacéutica/métodos , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/química , Docetaxel , Portadores de Fármacos/química , Sistemas de Liberación de Medicamentos/métodos , Humanos , Células KB , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Micelas , Nanomedicina/métodos , Tamaño de la Partícula , Tensoactivos/química , Taxoides/administración & dosificación
9.
Chin J Integr Med ; 24(6): 460-466, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29335861

RESUMEN

OBJECTIVE: To evaluate the potential pharmacokinetic interactions of the anticancer agent gefitinib (Iressa®) and the oriental medications Guipi Decoction (, GPD, Guibi-tang in Korean) and Bawu Decoction (, BWD, Palmul-tang in Korean). METHODS: Methylcellulose (MC, control), GPD (1,200 mg/kg), or BWD (6,000 mg/kg) was orally administered to rats either as a single dose or multiple doses prior to gefitinib administration. To examine the effects of a single dose of the herbal medicines, gefitinib (10 mg/kg) was orally administered after 5 min or 1 h of MC or the herbal medicine pretreatments. To examine the effects of the multiple doses of the herbal medicines, gefitinib (10 mg/kg) was orally administered following 7 consecutive days of the administration of MC or each herbal medicine. The plasma concentrations of gefitinib were determined with liquid chromatography-tandem mass spectrometry assay. The plasma concentration-time profiles of gefitinib were analyzed with a noncompartmental analysis. RESULTS: Gefitinib was rapidly absorbed and showed a monoexponential decline with an elimination half-life of 3.7-4.1 h. The pharmacokinetics of gefitinib was not affected by GPD pretreatment. However, a significantly lower maximum plasma concentration (Cmax, P<0.05) and area under the curve (P<0.05), and a delayed time to reach Cmax (Tmax, P<0.01) were observed in both single- and multipledose BWD-pretreated rats compared with the control rats. CONCLUSIONS: BWD and not GPD might delay and interfere with gefitinib absorption. Further evaluations of the clinical significance of these findings are needed.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Quinazolinas/administración & dosificación , Quinazolinas/farmacocinética , Animales , Cromatografía Liquida , Relación Dosis-Respuesta a Droga , Gefitinib , Masculino , Quinazolinas/sangre , Ratas Sprague-Dawley , Espectrometría de Masas en Tándem , Factores de Tiempo
10.
Molecules ; 22(9)2017 Sep 07.
Artículo en Inglés | MEDLINE | ID: mdl-28880240

RESUMEN

S-1 (TS-1®) is an oral fluoropyrimidine anticancer agent containing tegafur, oteracil, and gimeracil. Sipjeondaebo-tang (SDT) is a traditional oriental herbal medicine that has potential to alleviate chemotherapy-related adverse effects. The aim of the present study was to evaluate the effect of SDT on the pharmacokinetics of S-1. Sprague-Dawley rats were pretreated with a single dose or repeated doses of SDT for seven consecutive days (1200 mg/kg/day). After the completion of pretreatment with SDT, S-1 was orally administered and plasma concentrations of tegafur, its active metabolite 5-FU, and gimeracil were determined by liquid chromatography-tandem mass spectrometry (LC/MS/MS). A population pharmacokinetic model was developed to evaluate the effect of SDT on pharmacokinetics of tegafur and 5-FU. Although a single dose of SDT did not have any significant effect, the absorption rate of tegafur decreased, and the plasma levels of 5-FU reduced significantly in rats pretreated with SDT for seven days in parallel to the decreased gimeracil concentrations. Population pharmacokinetic modeling also showed the enhanced elimination of 5-FU in the SDT-pretreated group. Repeated doses of SDT may inhibit the absorption of gimeracil, an inhibitor of 5-FU metabolism, resulting in enhanced elimination of 5-FU and decrease its plasma level.


Asunto(s)
Antimetabolitos Antineoplásicos/farmacocinética , Medicamentos Herbarios Chinos/farmacología , Ácido Oxónico/farmacocinética , Piridinas/farmacocinética , Tegafur/farmacocinética , Administración Oral , Animales , Antimetabolitos Antineoplásicos/química , Combinación de Medicamentos , Medicamentos Herbarios Chinos/administración & dosificación , Medicamentos Herbarios Chinos/química , Fluorouracilo/metabolismo , Interacciones de Hierba-Droga , Humanos , Masculino , Modelos Biológicos , Ácido Oxónico/química , Piridinas/química , Ratas Sprague-Dawley , Tegafur/química
11.
Molecules ; 22(9)2017 Sep 10.
Artículo en Inglés | MEDLINE | ID: mdl-28891960

RESUMEN

Gemcitabine and erlotinib are the chemotherapeutic agents used in the treatment of various cancers and their combination is being accepted as a first-line treatment of advanced pancreatic cancer. Hyangsayukgunja-tang (HYT) is a traditional oriental medicine used in various digestive disorders and potentially helpful to treat gastrointestinal adverse effects related to chemotherapy. The present study was aimed to evaluate the effect of HYT on the pharmacokinetics of gemcitabine and erlotinib given simultaneously in rats. Rats were pretreated with HYT at an oral dose of 1200 mg/kg/day once daily for a single day or 14 consecutive days. Immediately after pretreatment with HYT, gemcitabine and erlotinib were administered by intravenous injection (10 mg/kg) and oral administration (20 mg/kg), respectively. The effects of HYT on pharmacokinetics of the two drugs were estimated by non-compartmental analysis and pharmacokinetic modeling. The pharmacokinetics of gemcitabine and erlotinib were not altered by single dose HYT pretreatment. However, the plasma levels of OSI-420 and OSI-413, active metabolites of erlotinib, were significantly decreased in the multiple dose HYT pretreatment group. The pharmacokinetic model estimated increased systemic clearances of OSI-420 and OSI-413 by multiple doses of HYT. These data suggest that HYT may affect the elimination of OSI-420 and OSI-413.


Asunto(s)
Antineoplásicos/farmacocinética , Protocolos de Quimioterapia Combinada Antineoplásica , Desoxicitidina/análogos & derivados , Clorhidrato de Erlotinib/farmacocinética , Sustancias Protectoras/farmacocinética , Administración Oral , Animales , Antineoplásicos/sangre , Área Bajo la Curva , Disponibilidad Biológica , Biotransformación , Desoxicitidina/sangre , Desoxicitidina/farmacocinética , Esquema de Medicación , Interacciones Farmacológicas , Clorhidrato de Erlotinib/sangre , Masculino , Extractos Vegetales/química , Plantas Medicinales/química , Sustancias Protectoras/metabolismo , Quinazolinas/sangre , Ratas , Ratas Sprague-Dawley , Gemcitabina
12.
Chem Pharm Bull (Tokyo) ; 64(11): 1546-1554, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27803466

RESUMEN

Quetiapine (QTP) is an atypical antipsychotic drug commonly used to treat several psychiatric disorders and is metabolized into the active metabolite norquetiapine (NQTP). This study was designed to evaluate and compare the physicochemical properties, metabolic stability, brain distribution, and pharmacokinetics of QTP and NQTP. Compared to QTP, NQTP had a higher pKa, solubility, and rat liver microsomal stability, optimal log D and similar log P values. For pharmacokinetic evaluation, QTP and NQTP were administered orally and intravenously to rats at various doses. The plasma QTP and NQTP concentrations in rats were determined by a fully-validated liquid-chromatography tandem mass spectrometry (LC-MS/MS). Over the investigated dosing range, both QTP and NQTP showed linear pharmacokinetics. Following oral administration of the same dose, the area under the concentration-time curve (AUC0-∞) and maximum serum concentration (Cmax) were larger after NQTP administration compared to QTP administration. In addition, NQTP had a greater absolute oral bioavailability compared to QTP (15.6% vs. 0.63%, respectively). The brain-to-plasma concentration ratio was greater after NQTP administration compared to the QTP and NQTP ratios after QTP administration. NQTP administration results in increased systemic exposure and brain distribution compared to QTP administration. Future studies are needed to evaluate the pharmacologic and toxicologic effects of increased NQTP exposures.


Asunto(s)
Encéfalo/metabolismo , Dibenzotiazepinas/metabolismo , Dibenzotiazepinas/farmacocinética , Microsomas Hepáticos/metabolismo , Fumarato de Quetiapina/metabolismo , Fumarato de Quetiapina/farmacocinética , Administración Oral , Animales , Química Física , Dibenzotiazepinas/administración & dosificación , Estabilidad de Medicamentos , Concentración de Iones de Hidrógeno , Masculino , Microsomas Hepáticos/química , Fumarato de Quetiapina/administración & dosificación , Ratas , Ratas Sprague-Dawley , Solubilidad , Distribución Tisular
13.
Chem Pharm Bull (Tokyo) ; 64(8): 1108-17, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27477648

RESUMEN

The purposes of the present study were to develop a self-microemulsifying drug delivery system (SMEDDS) containing bortezomib, a proteasome inhibitor. The solubility of the drug was evaluated in 15 pharmaceutical excipients. Combinations of oils, surfactants and cosurfactants were screened by drawing pseudo-ternary phase diagrams. The system exhibiting the largest region of microemulsion was considered optimal. Bortezomib SMEDDS spontaneously formed a microemulsion when diluted with an aqueous medium with a median droplet size of approximately 20-30 nm. In vitro release studies showed that the SMEDDS had higher initial release rates for the drug when compared with the raw drug material alone. Measurement of the viscosity, size, and ion conductivity indicated that a phase inversion from water in an oil system to oil in a water system occurred when the weight ratio of the water exceeded 30% of the entire microemulsion system. In a pharmacokinetics study using rats, the bortezomib microemulsion failed to improve the bioavailability of the drug. The reason was assumed to be degradation of the drug in the microemulsion in the gastrointestinal tract. However, bortezomib in Labrasol(®) solution (an aqueous solution containing 0.025% Labrasol(®)) showed significantly increased area under the curve from 0-24 h (AUC0-24 h) and maximum plasma concentration (Cmax) values compared to the drug suspension. The findings of this study imply that oral delivery of a bortezomib and colloidal system containing Labrasol(®) could be an effective strategy for the delivery of bortezomib.


Asunto(s)
Bortezomib/administración & dosificación , Bortezomib/farmacocinética , Composición de Medicamentos , Sistemas de Liberación de Medicamentos/métodos , Animales , Disponibilidad Biológica , Emulsiones , Tracto Gastrointestinal/metabolismo , Glicéridos/química , Masculino , Tamaño de la Partícula , Ratas , Ratas Sprague-Dawley , Solubilidad , Propiedades de Superficie , Viscosidad
14.
Exp Dermatol ; 25(12): 977-982, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-27488812

RESUMEN

Ultraviolet (UV) irradiation is a major environmental factor affecting photoageing, which is characterized by skin wrinkle formation and hyperpigmentation. Although many factors are involved in the photoageing process, UV irradiation is thought to play a major role in melanogenesis. Tyrosinase is the key enzyme in melanin synthesis; therefore, many whitening agents target tyrosinase through various mechanisms, such as direct interference of tyrosinase catalytic activity or inhibition of tyrosinase mRNA expression. Furthermore, the highly selective calcium channel ORAI1 has been shown to be associated with UV-induced melanogenesis. Thus, ORAI1 antagonists may have applications in the prevention of melanogenesis. Here, we aimed to identify the antimelanogenesis agents from methanolic extract of guava leaves (Psidium guajava) that can inhibit tyrosinase and ORAI1 channel. The n-butanol (47.47%±7.503% inhibition at 10 µg/mL) and hexane (57.88%±7.09% inhibition at 10 µg/mL) fractions were found to inhibit ORAI1 channel activity. In addition, both fractions showed effective tyrosinase inhibitory activity (68.3%±0.50% and 56.9%±1.53% inhibition, respectively). We also confirmed that the hexane fraction decreased the melanin content induced by UVB irradiation and the ET-1-induced melanogenesis in murine B16F10 melanoma cells. These results suggest that the leaves of P. guajava can be used to protect against direct and indirect UV-induced melanogenesis.


Asunto(s)
Melanosis/prevención & control , Monofenol Monooxigenasa/antagonistas & inhibidores , Proteína ORAI1/antagonistas & inhibidores , Fitoterapia , Extractos Vegetales/uso terapéutico , Psidium/química , Animales , Línea Celular Tumoral , Cromatografía de Gases y Espectrometría de Masas , Células HEK293 , Humanos , Ratones , Extractos Vegetales/farmacología , Rayos Ultravioleta
15.
BMC Pharmacol Toxicol ; 17(1): 35, 2016 07 26.
Artículo en Inglés | MEDLINE | ID: mdl-27459959

RESUMEN

BACKGROUND: Fimasartan (FMS) is a potent angiotensin receptor blocker for the treatment of mild to moderate hypertension. This study aimed to evaluate the transfer of FMS to fetus and breast milk in rats. METHODS: In order to study the transfer to the fetus and nursing pup, pregnant and nursing maternal rats were administered with FMS by a constant intravenous infusion to reach target plasma concentrations of 200 ng/mL and 100 ng/mL. The concentrations of FMS in plasma, placenta, amniotic fluid, fetus, and milk were determined by a validated LC-MS/MS assay. RESULTS: Upon constant intravenous infusion, the plasma FMS concentration reached the target steady state concentrations (Css = 200 ng/mL and 100 ng/mL) in 24 h. The tissue-to-plasma partition coefficients (Kp) for placenta, amniotic fluid, and milk were obtained based on the observed FMS concentrations in the tissues and Css. The Kp values for all tissues were not different between high (Css = 200 ng/mL) and low (Css = 100 ng/mL) dose groups. While the mean Kp of the placenta was 44.6-59.0 %, the mean Kp was 1.3-1.7 % for the amniotic fluid and 14.9-17.0 % for fetus. The mean Kp of milk was 10.4-15.2 %. CONCLUSIONS: Placental transfer and milk excretion of FMS was relatively lower compared to other angiotensin receptor blockers.


Asunto(s)
Antagonistas de Receptores de Angiotensina/sangre , Compuestos de Bifenilo/sangre , Lactancia/sangre , Intercambio Materno-Fetal/fisiología , Placenta/metabolismo , Pirimidinas/sangre , Tetrazoles/sangre , Antagonistas de Receptores de Angiotensina/administración & dosificación , Animales , Animales Recién Nacidos , Compuestos de Bifenilo/administración & dosificación , Femenino , Infusiones Intravenosas , Lactancia/efectos de los fármacos , Lactancia/metabolismo , Intercambio Materno-Fetal/efectos de los fármacos , Placenta/efectos de los fármacos , Embarazo , Pirimidinas/administración & dosificación , Ratas , Ratas Sprague-Dawley , Tetrazoles/administración & dosificación , Distribución Tisular/efectos de los fármacos , Distribución Tisular/fisiología
16.
Int J Nanomedicine ; 11: 1413-25, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27103799

RESUMEN

Investigation of potential therapeutics for targeting breast cancer stem cells (BCSCs) is important because these cells are regarded as culprit of breast cancer relapse. Accomplishing this kind of strategy requires a specific drug-delivery system using the distinct features of liposomes. Studies on targeted liposomal delivery systems have indicated the conjugation of hyaluronan (HA), a primary ligand for CD44 surface markers, as an appropriate method for targeting BCSCs. For this study, enriched BCSCs were obtained by culturing MCF-7 breast cancer cells in nonadherent conditions. The enriched BCSCs were challenged with HA-conjugated liposomes encapsulating gemcitabine (2, 2-difluoro-2-deoxycytidine, GEM). In vitro study showed that the HA-conjugated liposomes significantly enhanced the cytotoxicity, anti-migration, and anti-colony formation abilities of GEM through targeting of CD44 expressed on BCSCs. In pharmacokinetic study, area under the drug concentration vs time curve (AUC) of the immunoliposomal GEM was 3.5 times higher than that of free GEM, indicating that the HA-conjugated liposomes enhanced the stability of GEM in the bloodstream and therefore prolonged its half-life time. The antitumor effect of the immunoliposomal GEM was 3.3 times higher than that of free GEM in a xenograft mouse model, probably reflecting the unique targeting of the CD44 receptor by HA and the increased cytotoxicity and stability through the liposomal formulation. Furthermore, marginal change in body weight demonstrated that the use of liposomes considerably reduced the systemic toxicity of GEM on normal healthy cells. Taken together, this study demonstrates that HA-conjugated liposomes encapsulating GEM show promise for the therapy of breast cancer in vitro and in a xenograft model by targeting the BCSCs.


Asunto(s)
Antimetabolitos Antineoplásicos/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Desoxicitidina/análogos & derivados , Ácido Hialurónico/química , Liposomas/química , Células Madre Neoplásicas/efectos de los fármacos , Animales , Antimetabolitos Antineoplásicos/química , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Desoxicitidina/química , Desoxicitidina/farmacología , Sistemas de Liberación de Medicamentos , Femenino , Semivida , Humanos , Células MCF-7 , Ratones , Ratones Desnudos , Células Madre Neoplásicas/patología , Ensayos Antitumor por Modelo de Xenoinjerto , Gemcitabina
17.
Carcinogenesis ; 36(12): 1561-71, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26442525

RESUMEN

Epithelial ovarian cancer (EOC) commonly acquires resistance to chemotherapy, and this is the major obstacle to the better prognosis. Elucidating the molecular targets altered by chemotherapy is critically required to understand and overcome drug resistance. As a drug combination including paclitaxel is a prevalent prescription for treatment of EOC, to uncover gene expression altered in paclitaxel-resistant EOC, we analyzed multidirectional microarray profiles in both EOC cell lines and patients with paclitaxel resistance. Cyclin-dependent kinase 1 (CDK1) was found to be a potential target of transcription factors to regulate paclitaxel resistance. As a result of the subsequent pharmacogenomics analysis, CDK1 inhibitor alsterpaullone was also indicated as a promising chemical that may be used in combinatorial therapies to reverse paclitaxel-induced chemoresistance. Although a CDK1 inhibitor has the potential to kill cancer cells, short-term treatment over 2 weeks at sublethal doses effectively induced cell death only upon additional treatment with paclitaxel. A prominent reduction in the tumor growth rate was observed upon paclitaxel subsequent to alsterpaullone treatment in EOC xenograft model. Thus, we suggest that inhibition of CDK1 with alsterpaullone may be a novel therapeutic method to reverse paclitaxel-induced resistance in ovarian cancer cells.


Asunto(s)
Antineoplásicos/farmacología , Benzazepinas/farmacología , Quinasas Ciclina-Dependientes/metabolismo , Indoles/farmacología , Neoplasias Glandulares y Epiteliales/enzimología , Neoplasias Ováricas/enzimología , Paclitaxel/farmacología , Animales , Apoptosis , Proteína Quinasa CDC2 , Carcinoma Epitelial de Ovario , Línea Celular Tumoral , Quinasas Ciclina-Dependientes/antagonistas & inhibidores , Resistencia a Antineoplásicos/efectos de los fármacos , Femenino , Humanos , Ratones Endogámicos C57BL , Neoplasias Glandulares y Epiteliales/tratamiento farmacológico , Neoplasias Ováricas/tratamiento farmacológico , Ensayos Antitumor por Modelo de Xenoinjerto
18.
Bioorg Med Chem Lett ; 25(5): 1129-34, 2015 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-25637363

RESUMEN

Six new phenolics, scutellariosides A-F (1-3, 5-6, and 8), together with six known compounds (4, 7, 9-12) were isolated from the whole plant of Scutellaria indica (Labiatae). The chemical structures of these compounds were determined by spectroscopic analyses including 2D NMR. Their anti-inflammatory activities were evaluated against LPS-induced NO production in macrophage RAW 264.7 cells. Among them, compounds 10-12 had inhibitory effects with IC50 values ranging from 7.2 to 27.8µM. Compound 12 reduced LPS-induced iNOS expression in a dose-dependent manner.


Asunto(s)
Antiinflamatorios/química , Antiinflamatorios/farmacología , Macrófagos/efectos de los fármacos , Fenoles/química , Fenoles/farmacología , Scutellaria/química , Animales , Antiinflamatorios/aislamiento & purificación , Línea Celular , Flavonoides/química , Flavonoides/aislamiento & purificación , Flavonoides/farmacología , Lipopolisacáridos/inmunología , Macrófagos/inmunología , Ratones , Óxido Nítrico/antagonistas & inhibidores , Óxido Nítrico/inmunología , Óxido Nítrico Sintasa de Tipo II/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo II/inmunología , Fenoles/aislamiento & purificación , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología
19.
Talanta ; 131: 46-54, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25281071

RESUMEN

Acrylamide (AA) is a heat-generated food toxicant formed when starchy foods are fried or baked. This study describes a simple and sensitive liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of AA and its active metabolite, glycidamide (GA) in rat plasma, urine, and 14 different tissues. The assay utilized a simple method of protein precipitation and achieved a lower limit of quantification of 5, 10 and 25 ng/mL of AA and 10, 20 and 100 ng/mL of GA for plasma, tissues and urine, respectively. The assay was fully validated to demonstrate the linearity, sensitivity, accuracy, precision, process recovery, and stability using matrix matched quality control samples. The mean intra- and inter-day assay accuracy was 91.6-110% for AA and 92.0-109% for GA, and the mean intra- and inter-day assay precisions were ≤ 10.9% for AA and ≤ 8.60% for GA. The developed method was successfully applied to a pharmacokinetic study of AA and GA following intravenous and oral administration of AA in rats. Tissue distribution characteristics of AA and GA were also determined under steady-state conditions.


Asunto(s)
Acrilamida/análisis , Acrilamida/farmacocinética , Cromatografía Liquida/métodos , Compuestos Epoxi/análisis , Compuestos Epoxi/farmacocinética , Espectrometría de Masas en Tándem/métodos , Acrilamida/administración & dosificación , Administración Oral , Animales , Compuestos Epoxi/administración & dosificación , Masculino , Ratas , Ratas Sprague-Dawley , Suero/química , Distribución Tisular , Urinálisis
20.
Artículo en Inglés | MEDLINE | ID: mdl-25530781

RESUMEN

The potential pharmacokinetic (PK) interaction of conventional western drug, baclofen, and oriental medications Oyaksungisan (OY) and Achyranthes bidentata radix (AB) extract for the treatment of spasticity has been evaluated. Rats were pretreated with distilled water (DW), OY, or AB extract by oral administration every day for 7 days. After 10 min of the final dose of DW or each herbal medication, baclofen (1 mg/kg) was given by oral administration and plasma concentrations of baclofen were determined by LC/MS/MS. The plasma baclofen concentration-time profiles were then analyzed by noncompartmental analysis and a population PK model was developed. Baclofen was rapidly absorbed, showed biexponential decline with elimination half-life of 3.42-4.10 hr, and mostly excreted into urine. The PK of baclofen was not affected by AB extract pretreatment. However, significantly lower maximum plasma concentration (C max) and longer time to reach C max (T max) were observed in OY pretreated rats without changes in the area under the curve (AUC) and the fraction excreted into urine (F urine). The absorption rate (K a ) of baclofen was significantly decreased in OY pretreated rats. These data suggested that repeated doses of OY might delay the absorption of baclofen without changes in extent of absorption, which needs further evaluation for clinical significance.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...